STING1 and neoplasm: developed a manganese‐silica nanoplatform for the co‐delivery of tumor neoantigen peptides, STING agonist CDN, and Mn2+ adjuvants, aiming to enhance synergetic cancer immunotherapy.[100f] The nanoplatform was engineered by synthesizing hollow mesoporous silica nanoparticles (HMSNs) with large pore sizes, which were surface‐coated with manganese oxide (MnOx) nanoparticles.